35 results about "Orciprenaline" patented technology

The application discloses a preparation method and application of a conjugate targeting pelvic autonomic nerves, wherein the conjugate is NE-RH formed by coupling of rhein and norepinephrine, the conjugate can realize precise targeting of norepinephrine neurons, improve the accumulation effect of RH in the norepinephrine neurons, and further enhance the nerve protection effect of RH. The conjugate has a molecular weight of less than 1000 Da, can help to penetrate the blood-brain barrier, and can avoid the defects of being easily removed by a mononuclear phagocyte system and having a short half-life. The production process of the conjugate is simple, the chemical coupling reaction is clear, the yield can reach 38%, and the purity of the product is greater than 99%, so that the conjugate is convenient to popularize and use. The conjugate and the preparation method have important significance for the damage repair of pelvic autonomic nerves.

The invention belongs to the technical field of human body electroencephalogram signal processing and brain regulation and control, and provides a noradrenaline oscillation time-frequency-phase three-dimensional coupling sleep coordinated regulation and control device which comprises the following steps: calculating a three-dimensional coupling coefficient by combining a time domain correlation coefficient, a frequency domain correlation coefficient and an instantaneous phase difference between multi-modal physiological signals; determining the coupling state of the signal based on the three-dimensional coupling coefficient and a preset threshold value; predicting to obtain an optimal regulation factor and a modal weight based on a coupling coefficient matrix constructed based on a time domain correlation coefficient and a frequency domain correlation coefficient and a constructed three-dimensional coupling double-layer optimization architecture in combination with the multi-modal physiological signal; calculating the optimized stimulation intensity in combination with the modal weight, the optimal regulation factor and the multi-modal signal characteristic parameters; and adaptively selecting a stimulation mode and outputting a stimulation signal according to the coupling state of the current multi-mode signal and the optimized stimulation intensity. Accurate matching of stimulation parameters and nerve-blood vessel-cerebrospinal fluid system collaborative rhythm is realized.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The application relates to a reagent combination for detecting depression, a manufacturing method, a detection system and application thereof, and belongs to the technical field of instrument detection. The reagent combination for detecting depression comprises a calibrator, a quality control sample and an extraction solution of a to-be-detected compound serving as a biomarker; wherein the to-be-detected compound is at least three kinds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine and norepinephrine. The reagent combination for detecting depression and the detection system can significantly improve the accuracy of diagnosis, are convenient to detect, have good repeatability of detection data, are high in specificity, and are accurate in clinical diagnosis results.

The invention belongs to the technical field of human body electroencephalogram signal processing and brain regulation and control. The invention provides an ultrasonic-electrical stimulation collaborative lymphatic system enhanced closed-loop regulation and control system, which integrates noradrenaline oscillation core driving signals to realize sleep staging and conversion detection, decides an ultrasonic-electrical stimulation collaborative mode based on a staging coupling index, completes parameter linear transition in a conversion period, and improves sleep quality. Stimulation parameters are dynamically optimized in combination with reinforcement learning and a PID fusion algorithm. According to the device, the defects of core signal deficiency, inaccurate stimulation coordination, one-sided coupling analysis and poor safety adaptability of an existing device are overcome, the lymphatic system metabolic waste removal efficiency is remarkably improved, the sleep interruption risk is reduced, regulation and control are accurate, safety and noninvasive are achieved, the device is suitable for prevention and adjuvant therapy of neurodegenerative diseases such as Alzheimer's disease, and the device has a wide application prospect. And the method can also be expanded to be used for lymphatic-like function mechanism research and early disease screening.

The invention relates to a method for the synthesis of (1R)-2-(dibenzylamino)-1-(3,4- dibenzyloxyphenyl)ethanol of formula (I): (I), to said compound of formula (I), and to the use thereof as an intermediate in the synthesis of noradrenaline.

The application discloses application of a norepinephrine inhibitor in preparation of a medicine for treating or relieving corneal limbal stem cell deficiency, and belongs to the technical field of medicines.The experiment proves that sympathetic nerves are excessively activated in a mouse model of corneal limbal stem cell deficiency, and the release of norepinephrine is increased, and the experiment proves that 6-hydroxydopamine hydrochloride can destroy sympathetic nerves to inhibit the release of norepinephrine, and a tyrosine hydroxylase inhibitor can inhibit the synthesis of norepinephrine, and both can further relieve the symptoms of corneal limbal stem cell deficiency.The norepinephrine inhibitor can improve the corneal limbal microenvironment, reduce corneal neovascularization, reduce corneal epithelialization, enhance corneal transparency and relieve corneal edema, and provides a new direction and a new way for the pathogenic mechanism and intervention target of corneal limbal stem cell deficiency, and has a wide application prospect.

The invention relates to the technical field of analysis and detection, in particular to a kit and a method for extracting catecholamine and metabolites thereof based on a paramagnetic particle method and a method for detecting catecholamine and metabolites thereof by LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry). The kit comprises magnetic beads, an activating solution, an eluent, a washing solution, a leacheate I, a leacheate II and a derivatization reagent, the catecholamine and the metabolite thereof comprise one or more of dopamine hydrochloride, epinephrine, noradrenaline hydrochloride, methoxynoradrenaline hydrochloride, methoxyepinephrine hydrochloride and 3-methoxytyramine hydrochloride. The in-vivo concentration of catecholamine and metabolites thereof in human plasma and urine is detected in a high-flux manner by adopting a magnetic bead and derivation method, and the kit has the characteristics of high sensitivity, good repeatability, high accuracy, good specificity and the like.

The invention relates to the field of biological medicine, in particular to application of a quinic acid derivative. The quinic acid derivative comprises one or two of 3-O-p-coumaroyl quinic acid and 4-O-p-coumaroyl quinic acid, and the quinic acid derivative comprises one or two of 3-O-p-coumaroyl quinic acid and 4-O- The applications include treatment and / or prevention of depression. The quinic acid derivatives 3-O-p-coumaroyl quinic acid and 4-O-p-coumaroyl quinic acid can be used for improving the behavioristics of depressive mice; the compound can significantly increase dopamine and noradrenaline in the brain of a depressive mouse, reduce the levels of inflammatory factors IL-6 and TNF-alpha in the brain of the depressive mouse, increase the intestinal microbial diversity of the depressive mouse and significantly increase the BDNF level in the brain of the depressive mouse, and can be used as a drug for treating and / or preventing depression.

The invention discloses a method for rapidly and simultaneously detecting catecholamine substances and creatinine in urine, relates to the technical field of clinical content and concentration analysis and detection of nerve substances, and adopts LC-MS / MS (liquid chromatography-mass spectrometry / mass spectrometry) to perform system integration development of multiple indexes. Seven items, including dopamine, epinephrine, noradrenaline, alphinephrine, noradrenaline, homovanillic acid and vanillic mandelic acid, of urine catecholamine and metabolites are developed and used for detecting pheochromocytoma and paraganglioma; the seven items include the dopamine, the epinephrine, the noradrenaline, the alphinephrine, the homovanillic acid and the vanillic mandelic acid; seven indexes can be detected at a time, the kit can be used for detecting random urine, great convenience is brought to patients, meanwhile, the seven indexes are analyzed together, and specificity and sensitivity of PPGL detection are improved; random urine detection needs the ratio of seven indexes to creatinine, creatinine in urine is often used as an internal reference and is used for concentration correction when substances in urine are excreted, the concentration of catecholamine and catecholamine metabolites in urine is corrected according to the content of creatinine in urine, and the influence of renal functions and drinking water factors on results is reduced.

The invention provides carbon-14-labeled epinephrine and a preparation method thereof, carbon-14-labeled noradrenaline and a preparation method thereof, and belongs to the field of radioactive chemistry. The invention provides a carbon-14 labeled epinephrine or a carbon-14 labeled noradrenaline, wherein the carbon-14 label is located at the a position of the benzene ring of the epinephrine or the noradrenaline. According to the present invention, the epinephrine and the noradrenaline are subjected to carbon-14 labeling, such that the metabolite ratio can be quantitatively analyzed, the dynamic conversion rule of the metabolite in the human body can be revealed, the drug administration scheme can be easily optimized, the toxicological mechanism can be easily clarified, the theoretical basis can be provided for the clinical safety application, and the scientific development of the first-aid drug can be promoted.

The invention discloses application of a ganoderma lucidum extract in preparation of a product for improving skin problems, bidirectional regulation of skin homeostasis is realized through a dual-action mechanism, on one hand, conversion of corticosterone to cortisol is inhibited, and on the other hand, the skin homeostasis is inhibited; the problems of skin barrier injury, skin basement membrane injury, excessive sebum secretion, accelerated aging and the like caused by excessive cortisol are relieved; on the other hand, by inhibiting differentiation of macrophages induced by noradrenaline to inflammation phenotypes, the cortisol level is reduced, meanwhile, the skin inflammation response excited by early pressure is effectively controlled, and bidirectional regulation of skin homeostasis is achieved.

The invention discloses a fluorescent probe as shown in a formula I or II for detecting noradrenaline and epinephrine and application of the fluorescent probe in cell imaging and biosensing. The fluorescent probe for detecting noradrenaline can be specifically combined with noradrenaline, two-channel ratio-type fluorescence change is presented, a ratio-type signal has a self-calibration function, and higher accuracy is provided for quantitative analysis. The fluorescent probe for detecting the epinephrine can be specifically combined with the epinephrine and shows low-background opening type fluorescence change. The fluorescent probe has high sensitivity and selectivity, can realize quantitative detection of noradrenaline and epinephrine in serum and fluorescence imaging in cells, has the potential to be used as an effective tool for evaluating the sympathetic nerve activity degree in diseases such as hypertension, has a wide application prospect, and has a wide application prospect. And the detection means of catecholamine substances are enriched.

The invention belongs to the field of microbial technology and medicine, and particularly relates to an adhesive engineering yeast probiotic preparation as well as a preparation method and application thereof. The engineering saccharomycetes for efficiently expressing cantharides yellow is constructed by applying a synthetic biological technology. On the basis, the adhesion engineering yeast probiotics MBPSc22 are prepared through noradrenaline auto-polymerization, and the survival rate and retention capacity of the engineering yeast in gastrointestinal tracts are improved while the macrophage targeting capacity of the engineering yeast is not damaged. The adhesive engineering probiotic preparation can express canthaxanthin, directionally remove active oxygen at an inflammation part, reduce the inflammation level, increase the abundance and diversity of intestinal microorganisms, optimize the structure of the intestinal microorganisms and recover the steady state of the intestinal microorganisms, so that the aim of treating colitis is fulfilled.

The invention comprises a method of treatment of CNS disorders by a pharmaceutical agent exhibiting combined noradrenergic, serotonergic or dopaminergic reuptake transporter inhibitory and μ-opioid agonistic activity.

The invention belongs to the technical field of human body electroencephalogram signal processing and brain regulation and control, and provides a sleep stage self-adaptive multi-mode closed-loop regulation and control system which controls noradrenaline signals to be preset fixed oscillation frequency in a non-eyeball rapid movement sleep stage. Controlling the coherence of noradrenaline and delta wave and the coherence of noradrenaline and cerebral blood flow to be not less than corresponding preset values; in the sleep period of quick movement of eyeballs, the noradrenaline signal oscillation frequency is controlled to be increased, and the amplitude is reduced; in the conversion period, the delta wave power is controlled to be reduced, the theta wave is controlled to be increased, and the noradrenaline oscillation frequency is switched. NE oscillation and sleep staging self-adaption are integrated, so that the NREM-stage lymphatic clearing efficiency is improved, the cortex A content is reduced, the tau protein content is reduced, the REM-stage sleep interruption rate is reduced, the staging conversion success rate is 100%, the sleep continuity is improved compared with that of a traditional device, and effective physiological driving of different sleep stages is achieved.

The invention discloses a high-sensitivity DPJ-CE-MS method for detecting neurotransmitters and histamine metabolites, a kit and application, and belongs to the technical field of life analysis and detection. According to the method, a dynamic pH linkage on-line enrichment technology is adopted, alkaline ammonia water and a sample are sequentially injected, and effective pre-concentration of various target objects is achieved in a capillary tube. The background electrolyte and sheath fluid taking formic acid-methanol as a system, and key conditions such as separation voltage, electrospray voltage and the like are optimized. The method combines the advantages of high-efficiency separation of capillary electrophoresis and high-sensitivity and high-specificity detection of mass spectrum, and simultaneous analysis of 11 trace substances such as noradrenaline, glutamic acid, gamma-aminobutyric acid, 5-hydroxytryptamine, histamine and metabolites thereof in the cerebrospinal fluid is realized. Methodology verification shows that the method has excellent sensitivity, precision and accuracy, the detection limit is as low as 0.05-5 ng / mL, and a reliable analysis tool is provided for neuroscience basic research and discovery of biomarkers of related diseases.

The invention discloses puerarin acid ester derivatives with a sleep promoting function as well as a preparation method and application of the puerarin acid ester derivatives. The puerarin acid ester derivative has the following molecular structural formula, the L-tryptophan is combined with puerarin through chemical modification, so that a plurality of original hydrophilic groups are esterified and blocked, the lipid solubility is greatly improved, the bioavailability is improved, meanwhile, the content regulation and control of three neurotransmitters, namely 5-hydroxytryptamine, dopamine and noradrenaline are synergistically enhanced, and the bioavailability of the puerarin-L-tryptophan-puerarin-L-tryptophan-puerarin-L-tryptophan-puerarin-L-tryptophan-puerarin-L-tryptophan is improved. Compared with limitation of a single natural component in the aspect of sleep promoting function, the traditional Chinese medicine composition has remarkably enhanced medicine effect and typical application advantages; .

The invention relates to the field of medicine, in particular to a biomarker for diagnosis and prognosis evaluation of ventricular arrhythmia of a patient with dilated cardiomyopathy (DCM) and application of the biomarker. Matrix metalloproteinase-9 (MMP-9), 5-hydroxytryptamine (5-HT), noradrenaline (NE) and acetylcholine (ACh) are screened to serve as a biomarker combination, and by measuring the levels of MMP-9, 5-HT, NE and ACh in plasma, whether a DCM patient is accompanied with ventricular arrhythmia or not can be effectively recognized, the severity of the condition of the patient is evaluated, and the prognosis risk of the patient is predicted. The synergistic effect of MMP-9, 5-HT, NE and ACh can complement the defects of a single index, the diagnosis efficiency is improved, particularly, high specificity is achieved for ventricular arrhythmia, and an important basis is provided for risk stratification and individualized treatment of DCM patients.

The invention discloses a marker for predicting early pregnancy failure and application, the marker is a bloodlist amine substance and comprises 5-hydroxytryptamine, epinephrine and noradrenaline, whether the endometrial function is appropriate or not is judged according to the relative level of the bloodlist amine substance, and at least two of the following conditions are met. The lower limit is the physiological level of the human body; the relative concentration of serotonin in serum is greater than 200ng / ml after continuous detection for three times. According to the method, the level of amine substances in blood lists before pregnancy is utilized, the endometrial function and early embryo pregnancy outcome are predicted, pregnancy failure of fertility people is predicted, whether pregnancy is prepared or not or application of a new cycle assisted reproduction technology is guided, the pregnancy success rate of people is increased, especially the pregnancy failure people are predicted, and the method is suitable for popularization and application. Unnecessary economic burden is relieved, psychological pressure is reduced, and the patient can be guided to conduct body adjustment in the earlier stage.

The invention discloses a novel alkaloid Oreonudine G extracted from wild poppy and an application of the novel alkaloid Oreonudine G in preparation of an antidepressant drug. The preparation method of the Oreonudine G comprises the following steps: extracting with 95% ethanol, acidifying the extract, extracting with petroleum ether, adjusting the acid water layer to be alkaline with alkali liquor, extracting with chloroform, performing silica gel column chromatography on the chloroform extraction part, recrystallizing and the like to obtain the Oreonudine G. In-vitro pharmacological experiments show that the Oreonudine G can significantly inhibit reuptake of noradrenaline (NE), and the NE inhibition rate of the Oreonudine G is 43.0%, which is significantly higher than that of a positive drug amitriptyline (the inhibition rate is 35.5%). The invention provides an important candidate compound for developing efficient and novel antidepressant drugs.

The invention provides a method for synchronously detecting five catecholamines in urine based on derivatization nano electrospray ionization mass spectrometry. The method solves the technical problems that an existing detection method is tedious in step, long in detection time, limited in sensitivity and the like. The five kinds of catecholamine are respectively dopamine, noradrenaline, noradrenaline, noradrenaline and 3-methoxytyramine; the method comprises the following steps: S1, filtering a urine sample to be detected by a microfiltration membrane; s2, carrying out derivatization treatment on a filtrate filtered by the microfiltration membrane by adopting dansyl chloride to obtain a mixed solution containing a to-be-detected derivatization product; s3, carrying out liquid-liquid extraction on the mixed solution containing the to-be-detected derivatization product to obtain an organic phase; s4, blow-drying the organic phase, and re-dissolving with a re-dissolving solvent to obtain a re-dissolving solution; s5, directly detecting the redissolved solution by using a nano electrospray ion source in a mass spectrum, carrying out qualitative analysis by comparing secondary mass spectrum characteristic ion peaks, and carrying out quantitative analysis by using a standard curve external standard method; the method can be widely applied to the technical field of biological analysis and detection.

Provided herein are methods and compositions for treating, alleviating, or preventing post-traumatic stress disorder (PTSD). The therapeutic methods and compositions described herein include treating, alleviating, or preventing PTSD using at least one noradrenaline inhibitor and at least one endosensory antigen. The therapeutic methods and compositions described herein further comprise the use of at least one alpha2A-adrenergic receptor agonist and at least one magical agent to treat, alleviate or prevent PTSD.

The invention discloses a preparation method and application of a targeted pelvic autonomic nerve conjugate, the conjugate is NE-RH formed by coupling rhein and noradrenaline, the conjugate can achieve precise targeting of noradrenalgic neurons, the gathering effect of RH in the noradrenalgic neurons is improved, and the targeted pelvic autonomic nerve conjugate has the advantages that the targeted pelvic autonomic nerve conjugate can be used for preparing the targeted pelvic autonomic nerve conjugate. The nerve protection effect of the RH is further enhanced. The molecular weight of the conjugate is 1t; the molecular weight is 1000 Da, which is helpful for penetrating the blood brain barrier, and can avoid the defects of easy removal by a mononuclear phagocytic system and short half-life period. The production process of the conjugate is simple, the chemical coupling reaction is clear, the yield can reach 38%, and the product purity is gt; and the method is convenient to popularize and use. The conjugate and the preparation method thereof disclosed by the invention have important significance on damage repair of pelvic autonomic nerves.

A composition containing a mixture of oligomers or co-oligomers obtained by exposing an indolium-based monomer, optionally together with an additional monomer selected from dopamine, L-dopa, norepinephrine, serotonin, and a mixture thereof, to a basic buffer. The composition may further contain a hydrophobic substance such as a drug or dietary supplement, stabilized by the oligomers above.

This invention belongs to the field of physical therapy technology for Parkinson's disease, and provides a non-invasive closed-loop feedback vagus nerve electrical stimulation system for the prevention and treatment of Parkinson's disease. The system includes: a high-frequency electrical stimulator hardware subsystem, transcutaneous nerve stimulation electrodes, a respiratory and heart rate signal acquisition and closed-loop feedback subsystem, and a high-frequency electrical stimulator software subsystem. This invention uses kilohertz stimulation pulses to bidirectionally modulate the vagus nerve, activating afferent C fibers and initiating the anti-inflammatory neural pathway of locus coeruleus noradrenergic neurons, thus alleviating central inflammation. Simultaneously, it blocks A and B efferent fibers, inhibiting mediated α-synuclein retrograde axonal transport. Through multimodal physiological signal monitoring and embedded intelligent algorithms, it achieves real-time, closed-loop, and personalized control of stimulation parameters and automatic switching of stimulation modes, optimizing efficacy and improving safety. Through adhesive electrodes and acquisition devices, it achieves completely non-invasive, wearable, and home-based treatment.

The invention, which belongs to the technical field of automatic driving safety control, discloses an automatic driving safety control method based on double-neurotransmitter cooperative regulation and control, comprising the following steps: acquiring multi-modal environment data of a lane scene for feature fusion, generating a virtual scene through a hybrid strategy network, quantifying collision risk and environment uncertainty through a world model, and determining the collision risk and the environment uncertainty; obtaining a fear emotion stimulation value; the concentrations of noradrenaline and 5-hydroxytryptamine are dynamically adjusted on the basis of a fear emotion stimulation value, a stress reaction mechanism is triggered when the concentration of noradrenaline is high, a deep deterministic strategy gradient algorithm is combined with an action safety layer, and an instantaneous safety action is forcibly generated through mixed integer optimization. And triggering a long-term planning mechanism when the concentration of the 2, 5-hydroxytryptamine is high, and generating an optimal action with controllable global risk through trust domain strategy optimization based on a security constraint reinforcement learning framework. According to the method, the problem of collaborative optimization of instantaneous safety and long-term planning of automatic driving in a complex scene can be solved.

The invention provides a monoamine transmitter reuptake inhibitor as well as a preparation method and a pharmaceutical composition thereof. The invention further relates to application of the compound or the pharmaceutical composition in preparation of drugs for preventing or treating related diseases mediated by dopamine DA, noradrenaline NE and 5-hydroxytryptamine 5-HT.

A kind of algorithm model for depression detection, detection system, program and storage medium.The training method of the artificial intelligence model includes: constructing artificial intelligence model, its input includes the concentration of 3-4 kinds of to-be-detected compounds selected from 5-hydroxyanthranilic acid, methionine, gamma-aminobutyric acid, 3,4-dihydroxyphenylacetic acid, 2-picolinic acid, quinolinic acid, kynurenine, 5-hydroxytryptamine, 3-hydroxykynurenine, 3-hydroxyanthranilic acid, dopamine, norepinephrine, homocysteine, and the output is the risk index of suffering from severe depression;Large sample data is used to train the artificial intelligence model.The AUC of the detection model of the application is greater than or equal to 0.95, even 0.99;Accuracy rate reaches more than 90%;High sensitivity;Algorithm is simple, iterative convergence is fast, is convenient for transplantation, can be embedded into detection system, also can be used as a single data processing unit, works using encryption key or external U disk mode.